Literature DB >> 20940416

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Yair Herishanu1, Patricia Pérez-Galán, Delong Liu, Angélique Biancotto, Stefania Pittaluga, Berengere Vire, Federica Gibellini, Ndegwa Njuguna, Elinor Lee, Lawrence Stennett, Nalini Raghavachari, Poching Liu, J Philip McCoy, Mark Raffeld, Maryalice Stetler-Stevenson, Constance Yuan, Richard Sherry, Diane C Arthur, Irina Maric, Therese White, Gerald E Marti, Peter Munson, Wyndham H Wilson, Adrian Wiestner.   

Abstract

Chronic lymphocytic leukemia (CLL), an incurable malignancy of mature B lymphocytes, involves blood, bone marrow, and secondary lymphoid organs such as the lymph nodes (LN). A role of the tissue microenvironment in the pathogenesis of CLL is hypothesized based on in vitro observations, but its contribution in vivo remains ill-defined. To elucidate the effects of tumor-host interactions in vivo, we purified tumor cells from 24 treatment-naive patients. Samples were obtained concurrently from blood, bone marrow, and/or LN and analyzed by gene expression profiling. We identified the LN as a key site in CLL pathogenesis. CLL cells in the LN showed up-regulation of gene signatures, indicating B-cell receptor (BCR) and nuclear factor-κB activation. Consistent with antigen-dependent BCR signaling and canonical nuclear factor-κB activation, we detected phosphorylation of SYK and IκBα, respectively. Expression of BCR target genes was stronger in clinically more aggressive CLL, indicating more effective BCR signaling in this subtype in vivo. Tumor proliferation, quantified by the expression of the E2F and c-MYC target genes and verified with Ki67 staining by flow cytometry, was highest in the LN and was correlated with clinical disease progression. These data identify the disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL. This study is registered at http://clinicaltrials.gov as NCT00019370.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940416      PMCID: PMC3031480          DOI: 10.1182/blood-2010-05-284984

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation.

Authors:  Silvia Deaglio; Fabio Malavasi
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

2.  High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.

Authors:  Jan A Burger; Maite P Quiroga; Elena Hartmann; Andrea Bürkle; William G Wierda; Michael J Keating; Andreas Rosenwald
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

3.  Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.

Authors:  Rodrigo T Calado; Joshua A Regal; Mark Hills; William T Yewdell; Leandro F Dalmazzo; Marco A Zago; Peter M Lansdorp; Donna Hogge; Stephen J Chanock; Elihu H Estey; Roberto P Falcão; Neal S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-15       Impact factor: 11.205

Review 4.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

5.  Early growth response genes regulate B cell development, proliferation, and immune response.

Authors:  Murali Gururajan; Alan Simmons; Trivikram Dasu; Brett T Spear; Christopher Calulot; Darrell A Robertson; David L Wiest; John G Monroe; Subbarao Bondada
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

6.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

Review 7.  CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.

Authors:  J A Burger; A Peled
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

8.  Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.

Authors:  Till Seiler; Manuela Woelfle; Sophia Yancopoulos; Rosa Catera; Wentian Li; Katerina Hatzi; Carol Moreno; Marcela Torres; Santanu Paul; Hartmut Dohner; Stephan Stilgenbauer; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  Blood       Date:  2009-08-18       Impact factor: 22.113

9.  Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.

Authors:  Saman Hewamana; Thet Thet Lin; Clare Rowntree; Kamaraj Karunanithi; Guy Pratt; Robert Hills; Chris Fegan; Paul Brennan; Chris Pepper
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

10.  Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

Authors:  Meike Vogler; Michael Butterworth; Aneela Majid; Renata J Walewska; Xiao-Ming Sun; Martin J S Dyer; Gerald M Cohen
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

View more
  370 in total

1.  Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.

Authors:  J Melo-Cardenas; M Urquiza; T J Kipps; J E Castro
Journal:  Cancer Gene Ther       Date:  2012-03-09       Impact factor: 5.987

2.  Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

Authors:  Januario E Castro; Johanna Melo-Cardenas; Mauricio Urquiza; Juan S Barajas-Gamboa; Ramin S Pakbaz; Thomas J Kipps
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 3.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

Review 4.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

5.  Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Int J Cancer       Date:  2017-08-04       Impact factor: 7.396

6.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Authors:  P B Knudsen; B Hanna; S Ohl; L Sellner; T Zenz; H Döhner; S Stilgenbauer; T O Larsen; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528

7.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

8.  RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.

Authors:  Jingjing Xu; Peng Zhou; Wenjuan Wang; Aining Sun; Feng Guo
Journal:  J Mol Med (Berl)       Date:  2013-09-17       Impact factor: 4.599

Review 9.  Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.

Authors:  Allison Rosenthal
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

10.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.